RT Journal Article
SR Electronic
T1 Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253183
DO 10.1101/2021.03.09.21253183
A1 Tsuzuki, Shinya
A1 Hayakawa, Kayoko
A1 Uemura, Yukari
A1 Shinozaki, Tomohiro
A1 Matsunaga, Nobuaki
A1 Terada, Mari
A1 Suzuki, Setsuko
A1 Ohtsu, Hiroshi
A1 Asai, Yusuke
A1 Kitajima, Koji
A1 Saito, Sho
A1 Yamada, Gen
A1 Shibata, Taro
A1 Kondo, Masashi
A1 Izumi, Kazuo
A1 Hojo, Masayuki
A1 Mizoue, Tetsuya
A1 Yokota, Kazuhisa
A1 Nakamura-Uchiyama, Fukumi
A1 Saito, Fumitake
A1 Sugiura, Wataru
A1 Ohmagari, Norio
YR 2021
UL http://medrxiv.org/content/early/2021/09/06/2021.03.09.21253183.abstract
AB Objectives Although several randomised controlled trials have compared the efficacy of remdesivir with that of placebo, there is limited evidence regarding its effect in the early stage of nonsevere COVID-19 cases.Methods We evaluated the efficacy of remdesivir on the early stage of nonsevere COVID-19 using the COVID-19 Registry Japan, a nationwide registry of hospitalised COVID-19 patients in Japan. Two regimens (start remdesivir therapy within 4 days from admission vs. no remdesivir during hospitalisation) among patients without the need for supplementary oxygen therapy were compared by a three-step processing (cloning, censoring, and weighting) method. The primary outcome was supplementary oxygen requirement during hospitalisation. Secondary outcomes were 30-day fatality risk and risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO).Results The data of 12,657 cases met our inclusion criteria. The ‘start remdesivir’ regimen showed a lower risk of supplementary oxygen requirement (hazard ratio: 0.861, p < 0.001). Both 30-day fatality risk and risk of IMV/ECMO introduction were not significantly different between the two regimens (hazard ratios: 1.05 and 0.886, p values: 0.070 and 0.440, respectively).Conclusions Remdesivir might reduce the risk of oxygen requirement during hospitalisation in the early stage of COVID-19; however, it had no positive effect on the clinical outcome and reduction of IMV/ECMO requirement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Health and Labour Sciences Research Grant, Research for risk assessment and implementation of crisis management functions for emerging and re-emerging infectious diseases (19HA1003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NCGM ethics review board (NCGM-G-003494-0).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study would be available upon a reasonable request to the corresponding author.